Business Context and Reporting Period
Company: ChromaDex Corporation (formerly Cody Resources, Inc. following a reverse merger with ChromaDex, Inc. on June 20, 2008).
Reporting Period: Quarterly period ended June 28, 2008 (Six months ended June 28, 2008).
Business Overview: The Company creates and supplies botanical reference standards, phytochemical products, and related services for the functional food, pharmaceutical, personal care, and dietary supplement markets. The Company operates as a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 28, 2008 |
Six Months Ended June 30, 2007 |
Three Months Ended June 28, 2008 |
Three Months Ended June 30, 2007 |
|---|---|---|---|---|
| Sales (Revenue) | $2,258,601 | $2,203,980 | $1,198,885 | $997,087 |
| Gross Profit | $765,424 | $798,467 | $365,980 | $255,860 |
| Gross Margin | 33.9% | 36.2% | 30.5% | 25.7% |
| Operating Loss | $(741,230) | $(325) | $(625,952) | $(123,052) |
| Net Loss | $(744,582) | $(933) | $(621,676) | $(113,926) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.00) | $(0.03) | $(0.01) |
| Cash and Equivalents (Ending) | $2,415,620 | $196,479 | N/A | |
| Total Current Assets | $3,611,559 | $1,236,917 | ||
| Total Current Liabilities | $3,127,226 | $2,212,826 | N/A | |
| Notes Payable (Current) | $959,617 | $0 | ||
| Accumulated Deficit | $(5,840,062) | $(5,095,482) | N/A | |
| Stockholders' Equity | $2,014,646 | $396,315 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 20.2% in the three months ended June 28, 2008, compared to the prior year period, driven by increased demand for reference standards from food companies. Six-month sales remained relatively flat (2.5% increase).
- Profitability Deterioration: The Company shifted from near break-even operations in the prior year (Net loss of $933 for six months) to a significant Net Loss of $744,582 for the six months ended June 28, 2008.
- Expense Surge: Operating expenses increased significantly. General and Administrative expenses rose from $624,221 to $1,175,112 (six months), primarily due to one-time legal and accounting costs associated with the reverse merger and private placement, as well as increased insurance and compliance costs.
- Liquidity Improvement: Cash balances increased from $303,785 to $2,415,620, driven by net proceeds of approximately $3.29 million from the issuance of common stock in a private placement.
- Debt Incurrence: The Company incurred a new non-interest bearing note payable of $959,617 (discounted value) to Bayer AG in connection with a share repurchase prior to the merger.
Guidance, Outlook, and Risks
- Capital Resources: Management believes current cash and proceeds from the ongoing private placement (targeting $6 million total) will finance operations through Fall 2009. However, there is no assurance that additional financing will be available if needed.
- Strategic Outlook: The Company plans to expand service capacity, implement accreditation programs, and establish a GMP-compliant pilot plant. Growth is anticipated to be driven by upcoming FDA Good Manufacturing Practices (GMP) guidelines for the dietary supplement industry.
- Risks:
- Financing Risk: Inability to raise additional capital could force the Company to delay product expansion or curtail operations.
- Regulatory Risk: Uncertainty regarding the enforcement and interpretation of new FDA GMP regulations could impact demand for the Company's products.
- Going Concern: While the merger improved liquidity, the Company has incurred aggregate losses of $5.8 million since inception and relies on continued capital contributions.
- Unusual Items: The financial statements reflect a reverse merger with Cody Resources, Inc., resulting in a change of fiscal year-end and the elimination of historical accumulated deficits. Significant one-time costs related to this transaction and the private placement impacted the current period's results.
Investor Verification Checklist
- Private Placement Status: Verify the total capital raised to date against the $6 million target and the terms of the warrants issued to investors.
- Bayer Note Obligation: Confirm the repayment schedule and interest penalties for the $1,002,691 note due to Bayer AG on December 31, 2008.
- Related Party Payables: Review the $1.18 million owed to officers for unpaid compensation and the terms of repayment.
- Regulatory Impact: Assess the specific impact of FDA GMP enforcement timelines on the Company's projected revenue growth.
- Stock Dilution: Monitor the impact of outstanding warrants (approx. 2.2 million potential shares) and future equity issuances on shareholder dilution.